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ABSTRACT
Background
Graft-versus-host disease (GVHD) results from recognition of host antigens by donor T cells
following allogeneic hematopoietic cell transplantation (AHCT). Notably, histoincompatibility
between donor and recipient is necessary but not sufficient to elicit GVHD. Therefore, we tested
the hypothesis that some donors may be ‘‘stronger alloresponders’’ than others, and
consequently more likely to elicit GVHD.
Methods and Findings
To this end, we measured the gene-expression profiles of CD4
þ and CD8
þ T cells from 50
AHCT donors with microarrays. We report that pre-AHCT gene-expression profiling segregates
donors whose recipient suffered from GVHD or not. Using quantitative PCR, established
statistical tests, and analysis of multiple independent training-test datasets, we found that for
chronic GVHD the ‘‘dangerous donor’’ trait (occurrence of GVHD in the recipient) is under
polygenic control and is shaped by the activity of genes that regulate transforming growth
factor-b signaling and cell proliferation.
Conclusions
These findings strongly suggest that the donor gene-expression profile has a dominant
influence on the occurrence of GVHD in the recipient. The ability to discriminate strong and
weak alloresponders using gene-expression profiling could pave the way to personalized
transplantation medicine.
The Editors’ Summary of this article follows the references.
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Graft-versus-host disease (GVHD) is initiated by donor T
cell responses to host alloantigens [1–3]. However, the
occurrence and severity of GVHD are not determined solely
by the level of histoincompatibility between donor and
recipient. Thus, two major histocompatibility complex
(MHC)-identical individuals (excluding identical twins) or
two inbred strains of mice will display over 50 minor
histocompatibility antigen differences [4,5]. If histoincom-
patibility was sufﬁcient for triggering GVHD, the rate of
GVHD in MHC-matched recipients of allogeneic hemato-
poietic cell transplantation (AHCT) that receive no immu-
nosuppressive agents should therefore be 100%. Under these
conditions, however, GVHD was found in only 50% and 73%
of mouse and human recipients, respectively [6,7]. Even in
mouse MHC-mismatched AHCT models, some, but not all,
donor strains induce severe acute GVHD (aGVHD) [8,9].
Thus, histoincompatibility is necessary, but not sufﬁcient, to
elicit fatal GVHD. Recent evidence suggests that aside from
the mere presence of genetic polymorphisms, two host
factors may inﬂuence the severity of aGVHD and chronic
GVHD (cGVHD): elusive properties (for example, tissue
distribution) of the immunodominant host alloantigens [10]
and polymorphisms of host cytokine genes [11,12]. Another
nonexclusive and largely unexplored rationale would be that
some donors are ‘‘stronger alloresponders’’ than others
because of quantitative or qualitative differences in immune
responses. Indirect evidence for the latter hypothesis are
reports suggesting that several donor genetic polymorphisms
may correlate with GVHD severity [12].
The seminal studies of Biozzi and colleagues have shown
that the strength of B cell responses to natural immunogens
is under multigenic control [13,14]. Approximately ten
independently segregating loci endowed with additive effects
are responsible for the major (240-fold) multispeciﬁc differ-
ences separating high- and low-antibody responders [15,16].
No similar data are available for T cell responses in general,
and those against histocompatibility antigens in particular.
Since GVHD is by far the main barrier in AHCT [17–20],
identiﬁcation of high-risk donors would allow better donor
selection and tailoring of immunosuppressive regimens to
GVHD risk. In addition to complex genetic trait linkages, it
may also be assumed that environmental factors and donor
immune system histories may contribute toward determining
GVHD. While the latter two factors would be hidden from
the analysis of inherited genetic traits or gene-sequence
variation, they might be reﬂected in gene-expression
signatures. We therefore chose to measure the activity of a
broad range of genes with expression microarrays as a means
of surveying the overall molecular-state signature of the
donor immune system, independent of whether that state is
largely determined by inherited genetic factors, environ-
ment, donor history, or mixtures thereof. The objective of
our study was, therefore, to determine whether gene-
expression proﬁling could discriminate AHCT donors that
induced either aGVHD or cGVHD in their recipient host
from donors who did not. In other words, is it possible to
distinguish high from low alloresponders? Notwithstanding
the fundamental importance of that question, a positive
answer could pave the way to personalized transplantation
medicine.
Methods
Study Patients
Only patients with hematological malignancies and their
healthy sibling donors who were identical with regard to HLA
participated in this study (Table 1). The AHCT myeloablative
regimen consisted of cyclophosphamide (120 mg/kg) and total
body irradiation (12 Gy), or busulfan (16 mg/kg) and cyclo-
phosphamide (200 mg/kg). All patients received unmanipu-
lated peripheral blood–stem-cell grafts (mobilized with G-
CSF) and were given GVHD prophylaxis consisting of
cyclosporine A and short-course methotrexate [21]. Donor
blood samples were obtained one day prior to mobilization of
peripheral blood–progenitor cells with G-CSF. Diagnosis of
aGVHD and cGVHD was made after clinical evaluation and
histologic conﬁrmation according to previously reported
criteria [22–24]. Patients with grade 0 and grades I–IV
aGVHD were considered aGVHD  and þ, respectively.
Biopsies of skin and gut were carried out in 90% and 15%
of patients with aGVHD, respectively; overall, 95% of
participants with aGVHD had biopsies, including all patients
with grade I GVHD. All participants with cGVHD showed
extensive clinical GVHD [19]. Clinical protocols were
approved by the Human Subjects Protection Committee of
the Maisonneuve-Rosemont Hospital. Samples were obtained
with the informed consent of the patients.
RNA Isolation, Amplification, and Microarray Hybridization
CD4
þ and CD8
þ T cells were enriched from peripheral
blood mononuclear cells by positive isolation using magnetic
Table 1. Donor–Recipient Characteristics
Variables Subcategories Data
Total number donors/recipients 50/50
Recipient median age at
transplantation, y (range)
45 (19–58)
Donor median age at
transplantation, y (range)
40 (17–59)
Number of male recipients 30
Number of male donors 38
Disease numbers Acute lymphoblastic leukemia 3
Acute myelogenous leukemia 2
Chronic myelogenous leukemia 34
Myelodysplastic syndrome 2
Non-Hodgkin lymphoma 7
Other diseases 2
Acute GVHD 20
Grade I 8
S1L0GI0:4
S2L0GI0:4
Grade II 2
S0L0GI1:1
S3L0GI0:1
Grade III 7
S0L0GI2:2
S2L2GI0:1
S0L0GI3:4
Grade IV 3
S0L0GI4:1
S0L1GI4:1
S1L0GI4:1
Chronic GVHD (extensive) 32
SLGI: Staging of skin, liver, and gastrointestinal tract involvement by acute GVHD.
doi:10.1371/journal.pmed.0040023.t001
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Prediction of Graft-Versus-Host Diseasemicrobeads (Dynal, http://www.invitrogen.com). Sample RNA
was extracted using an RNA extraction kit (Qiagen, http://
www.qiagen.com), then ampliﬁed using the MessageAmp RNA
kit (Ambion, http://www.ambion.com), as per the manufac-
turers’ instructions. Universal human RNA (Stratagene, http://
www.stratagene.com) was ampliﬁed in the same way. Probes
for microarray hybridization were prepared by labeling 3 lg
of ampliﬁed RNA with Cy-3 (universal RNA; green values) or
Cy-5 (CD4
þ or CD8
þ T cells; red values) by reverse tran-
scription. Detailed information on the microarrays as well as
the labeling and hybridization procedures can be obtained at
The Microarray Centre of The Toronto University Health
Network (http://www.microarrays.ca/).
Microarray Data Preprocessing
Microarrays were scanned at 16 bits using the ScanArray
Express scanner (Packard Bioscience, http://las.perkinelmer.
com) at 10-lm resolution at 635 (red)- and 532 (green)-nm
wavelengths for Cy-5 and Cy-3, respectively, to produce image
(tiff) ﬁles that were quantiﬁed using Genepix Pro 6.0 image-
analysis software (Molecular Devices Corporation, http://www.
moleculardevices.com). Bad spots were ﬂagged manually
according to their morphologies. The results were saved as
Quantarray ﬁles where the intensity values ranged from 0 to
2
16   1 (65,535) units. The tiff and Quantarray ﬁles were
compressed and archived for permanent storage and further
analysis. The microarrays were then screened for quality, ﬁrst
by visual inspection of the array with ﬂagging of poor-quality
spots, and second with automated scripts that scanned the
quantiﬁed output ﬁles and measured overall density distri-
bution on each channel and number of ﬂagged spots. Box
plots and density-distribution plots were drawn and in-
spected. Each quantiﬁed output ﬁle was run through the
following preprocessing steps using the R language and
environment (http://www.r-project.org) and the Limma pack-
age [25]. For minimum-intensity ﬁltering, red and green
values were treated with a surrogate-value replacement policy
for estimating subthreshold values. For normalization within
arrays, the raw merged red and green channels were lowess-
normalized (grouped by print tip) and transformed to log2
ratios [26]. The commensurability of average brightness
between the arrays of a pool of arrays was then assured using
zero-centering of log-distributions normalization. For the
ImmunArray design (The Microarray Centre of The Toronto
University Health Network), each clone (gene) is represented
by two independent spots, to provide for internal replicates.
When both duplicate spots of a clone (gene) passed quality
control, the average value of the duplicate clones was
calculated and used as the representative value for that gene.
If only one of the clone duplicate spots passed quality control,
only that value was used in the downstream analysis. All data
were then represented as log10 (red/green) expression ratios
for further analysis.
Quantitative Real-Time-PCR
Total RNA was reverse transcribed in a ﬁnal volume of 50 ll
using the High Capacity cDNA Archive kit with random
primers (Applied Biosystems, http://www.appliedbiosystems.
com) as described by the manufacturer. Reverse-transcribed
samples were quantiﬁed using spectrophotometer measure-
ments, diluted to a concentration of 5 ng/ll, and stored at 20
8C. A reference RNA (human reference total RNA [Stratagene])
was also transcribed to cDNA and was used as the calibrator.
Gene-expression levels were determined using primer and
probe sets from Applied Biosystems (ABI Assays on Demand
[http://www.appliedbiosystems.com/]). The human glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) predeveloped TaqMan assay
(PN4326317E) was used as the endogenous control. PCR
reactions were performed using 4 ll of cDNA samples (20
ng), 5 ll of the TaqMan Universal PCR Master mix (Applied
Biosystems), and 0.5 ll of the TaqMan Gene Expression assays
(203) in a total volume of 10 ll. The ABI PRISM 7900HT
Sequence Detection system (Applied Biosystems) was used to
detect the ampliﬁcation level, and was programmed to an
initial step of 10 min at 95 8C, followed by 40 cycles of 15 s at 95
8C, and 1 min at 60 8C. All reactions were run in triplicate, and
the average values of the triplicates were used for quantiﬁca-
tion. The relative expression level of target genes was
determined by using the DDCT method. Brieﬂy, the CT
(threshold cycle) values of target genes were normalized to an
endogenous control gene (GAPDH) (DCT¼CTtarget CTGAPDH)
and compared with a calibrator (humanreference RNA):DDCT
¼ DCTsample   DCTcalibrator. Relative expression (RQ) was
calculated using the Sequence Detection system (SDS) 2.2.2
software (Applied Biosystems) and the formula RQ¼ 2
 DDCT.
Student’s t-Test and Linear Discriminant Analysis
The well-established univariate Student’s t-test can deter-
mine whether the differences in expression for each gene are
statistically signiﬁcantly different in the aGVHDþ versus the
aGVHD  and the cGVHDþ versus the cGVHD  sample
classes, respectively. Speciﬁcally, given knowledge of the
GVHDþ and GVHD  class arithmetic means and standard
deviations from measurements, the t-test provides the
probability or p-value of rejecting the null hypothesis of
equal class means, given the null hypothesis being true (i.e.,
that both sample classes are essentially indistinguishable and
derive from the same underlying distribution). It is also well
established in practice that the t-test is robust against
substantial departures from normality [27]. However, the t-
test does not address per se the question of the robustness of
class-prediction accuracy for a predictive model. A clinical
user of such a model would ultimately like to predict whether
a donor sample falls in the GVHDþor GVHD class, and what
the expected accuracy and robustness of such a prediction
would be. To this end, we used linear discriminant analysis
(LDA) to estimate the accuracy of GVHD predictive genes
discovered in microarray and quantitative real-time (qRT)-
PCR experiments [28]. In addition, we assessed the robustness
for all the genes validated by qRT-PCR by performing 500
independent instances of training-test dataset splits cross-
validation to determine empirically through computational
resampling the expected generalizable class-prediction accu-
racy on independent test datasets [29,30]. In LDA with
assumed equal class a priori probabilities, the boundary
between class P (GVHDþ) and class N (GVHD ) is determined
by the value of the separatrix, S, which is the point (in
univariate analysis) between the class P and N means that is
equidistant to both [28]. If the observed mean of class P is
smaller than the observed mean of class N, all values less than
or equal to S will be classiﬁed by the model as P, and all values
greater than S will be classiﬁed as N. When the observed mean
of class P is greater than the observed mean of class N, all
values greater or equal to S will be classiﬁed by the model as
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Prediction of Graft-Versus-Host DiseaseP, and all values smaller than S will be classiﬁed as N. For all
the samples that were classiﬁed by the model as P, the ones
that also correspond to known P samples in the measured
data constitute true positives, and the ones that correspond
to known N samples in the measured data constitute false
positives. For all the samples that were classiﬁed by the model
as N, the ones that also correspond to known N samples in the
measured data constitute true negatives, and the ones that
correspond to known P samples in the measured data
constitute false negatives. Accuracy rate is (true positives þ
true negatives)/total number of samples. Sensitivity is true
positives/(true positives þ false negatives), and speciﬁcity
denotes true negatives/(true negatives þ false positives).
Predictive Interaction Analysis
Predictive interaction analysis (PIA) was carried out on the
105 gene pairs formed by 15 genes that were individually
predictive of GVHD in both microarray and qRT-PCR
experiments. Gene pairs and single genes were compared as
to their ability to distinguish GVHDþ from GVHD  samples
according to the statistical methods outlined below.
Two-class discriminant analysis. Standard equations of
LDA [28] are employed for determining two-class separations
(GVHDþ versus GVHD ), based on single-gene or two-gene
abundances. Column vector x
!
represents the log10 abundan-
ces of a gene pair (mapping of gene pair abundances to a
single variable is deﬁned in PIA below). T denotes transpose.
The variable c1 denotes one known class (e.g., GVHDþ), and c2
denotes a second known class (e.g., GVHD ). The general two-
class linear discriminant equation [28] is:
fðx
!
Þ¼ð l
!
c2   l
!
c1Þ
T X
 1 x
!
þ l
!T
c1
X
 1 l
!
c1   l
!T
c2
X
 1 l
!
c2
  
=2 þ lnðPc2=P1Þ; ð1Þ
where gene pair vectors l
!
c1 and l
!
c2 are the respective class
means; R
 1 is the inverse of the gene pair by gene-pair data-
derived pooled covariance matrix R, which is the sample
number-weighted sum of the data-derived within-class cova-
riance matrices. Pc1 and Pc2 are the prior probabilities of the
two classes. The ln(Pc2/Pc1) term in Equation 1 is zero because
we set Pc2¼Pc1. In the LDA we are performing, the proportion
of c2 samples compared to c1 samples in the data is not
germane. Of relevance in the LDA are the individual sample
data values, the class means, and the within-class variations,
not the class prior probabilities per se. Setting Equation 1 to
zero deﬁnes the general equation for the separatrix L:
a
!T   x
!
þ c ¼ 0; ð2Þ
where parameter vector a
! T ¼ð l
!
c2   l
!
c1Þ
TR 1 and scalar
c ¼ðl
!T
c1R 1 l
!
c1   l
!T
c2R 1 l
!
c2Þ=2 are data-dependent con-
stants. The general L then can be written immediately in
slope/intercept form as
x2 ¼  ð a1=a2Þx1   c=a2; ð3Þ
where ½a1;a2 ¼ a
!T. However, in the PIA to be described
below we use a specialized, deliberately constrained form of
Equation 3. Namely, the separatrix L has slope 1 (synergistic
PIA [SPIA]), or þ1 (competitive PIA [CPIA]), and necessarily
bisects the chord between the two class means l
!
c1 and l
!
c2.
CPIA and SPIA. The product X 3 Y for gene X and gene Y
represents a synergistic phenomenological gene–gene inter-
action (SPIA), and the abundance ratio X/Y (or Y/X) for gene X
and gene Y represents a competitive phenomenological gene–
gene interaction (CPIA). We deﬁne x ¼ log10(X), y ¼ log10(Y),
and new coordinates or axes: u ¼ x þ y and v ¼ x   y. Class
separation in (x, y) with respect to univariate u is termed SPIA,
and class separation with respect to univariate v is termed
CPIA. PIA refers to either SPIA or CPIA. Hence, good class
separation in SPIA is demonstrated by good separation in (x,
y) by a separatrix u ¼ x þ y ¼ constant (equivalent to y ¼  x þ
constant, i.e., slope  1), and good class separation in CPIA is
demonstrated by good separation in (x, y) by a separatrix v¼x
 y¼constant (equivalent to y¼x constant, i.e., slopeþ1). Thus,
we apply LDA under models restricted to separatrices whose
slopes are constrained deliberately to  1o rþ1.
Classiﬁcation performance measures. We use straightfor-
ward sampling statistics to characterize class separation by p-
values, as well as by counts of correctly classiﬁed samples
relative to the total number of samples being classiﬁed
(univariate LDA accuracies). The class-separation perform-
ance of a gene pair (X,Y) in SPIA or CPIA can be assessed
readily on single axes x, y, u, and v. When samples in (x,y) are,
for example, projected onto the x-axis, classiﬁcation perform-
ance is assessed by the p-value returned by a simple
homoscedastic t-test for differences of two means. This is
computed analogously and separately for the y-, u-, and v-
axes. It is important—because of the biological interpreta-
tions offered by SPIA and CPIA—to focus on those gene pairs
for which two-class separation (as assessed by intercompar-
able p-values) is better in u or in v than in x and in y. Thus, we
seek gene pairs (X,Y) for which along the ‘‘single variable’’ u-
axis or v-axis, the classes separate better than along the x-axis
only and better than along the y-axis only.
Results
Experimental Model
In our quest for a GVHD-predictive signature, our prime
objective was to correlate global gene-expression proﬁling of
AHCT donor T cells with the occurrence of GVHD in
recipients. A secondary objective was to evaluate whether
the donor gene-expression proﬁle persisted long-term in the
recipient. Peripheral blood was obtained from 50 AHCT
donors pretransplant (referred to as day 0) and from 40
recipients on day 365 (ten recipients were dead by day 365)
(Figure 1). Donors and recipients were human leukocyte
antigen-identical siblings. Recipients were regarded as neg-
ative for aGVHD when they lived at least 100 days without
presenting GVHD. Recipients were considered negative for
cGVHD when they remained cGVHD-free for 365 days post-
AHCT. CD4
þ and CD8
þ T cell subsets were puriﬁed with
microbeads. Total RNA was puriﬁed, ampliﬁed, reverse
transcribed, and hybridized on microarrays developed by
The Microarray Centre of The Toronto University Health
Network. RNA from donor and recipient T cells was
hybridized on the human H19K array (19,008 expressed
sequence tags), and donor T cell RNA was also hybridized on
the ImmunArray (3,411 ESTs from immune-related genes).
The ImmunArray provides additional genes for better cover-
age of immune responses to complement the H19K array.
The success rate of gene-expression proﬁling studies
decreases with the degree of biological noise inherent to
the experimental system [31–34]. Accordingly, our study
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unlike recipients of solid organ grafts who inevitably present
organ failure (e.g., renal insufﬁciency), AHCT donors are
healthy individuals. This is important because serious ail-
ments (and their treatment) cause alterations in global gene
expression that are signiﬁcantly greater than the background
variation in normal gene expression [35]. Second, our studies
were performed on puriﬁed CD4
þ and CD8
þ T cells because
cell lineage is a primary determinant of gene-expression
proﬁle [36], and the transcriptome of CD4
þ and CD8
þ T cells
shows signiﬁcant differences [37]. Third, CD4
þ and CD8
þ T
cells are necessary and sufﬁcient for induction of antiminor
histocompatibility antigen GVHD [38,39], the clinical end-
point of this study. Fourth, AHCT recipients were treated in a
single center using standardized therapeutic regimens and
uniform criteria for diagnosis of GVHD.
Donor T Cell Gene-Expression Profiling Using Microarrays
We ﬁrst carried out eight searches for class-discriminating
genes using two methods, a statistical t-test and a specially
constrained LDA, over four class divisions. Class divisions
were, for CD4
þand CD8
þT cells: (i) recipients with no GVHD
versus those with aGVHD (with or without cGVHD); and (ii)
recipients with no GVHD versus those with cGVHD (with or
without aGVHD). Recipients were considered GVHD  only
when they presented no signs of GVHD after a minimum
follow-up of one year post-AHCT. We selected for analysis
genes showing a GVHD-predictive LDA accuracy (ability to
discriminate donors whose recipient presented GVHD or
not)   65% and class discrimination t-test p   0.05 (Figure
2A). Consistent with the notion that aGVHD strongly
correlates with cGVHD [19], many of the genes predictive
for aGVHD were also predictive for cGVHD (Figure 2B). A
substantial proportion of GVHD-predictive genes were
common to both CD4
þ and CD8
þ donor T cells (Figure 2C).
However, the fact that most GVHD-associated genes were
found in only CD4
þ or CD8
þ T cells supports the need to
analyze T cell subsets independently (Figure 2C). Among
genes emerging from the ImmunArray and H19K datasets,
those that are annotated and have a demonstrated or putative
function in T cell biology are listed in Table S1 (genes
overexpressed in GVHDþ relative to GVHD  donors) and
Table S2 (genes repressed in GVHDþ donors). Overall, the
numbers of genes that were up-regulated/down-regulated in
GVHDþ relative to GVHD  donors were 22/42 for CD4
þ T
cells and 31/40 for CD8
þT cells. About 60% of these genes are
involved in cell proliferation, signal transduction, or tran-
scription (unpublished data).
qRT-PCR Analyses of GVHD-Predictive Genes
Predictive value of single genes. To evaluate the validity of
predictive genes identiﬁed with microarrays, we performed
qRT-PCR analyses on fresh mRNA aliquots extracted from
donor CD4
þ (n¼33) and CD8
þ(n¼35) T cells. We focused on
cGVHD-predictive genes and tested a total of 26 genes,
including 24 genes present in Table S1 and Table S2. We
selected the latter 24 genes based on two criteria: they are
involved in cell proliferation and/or cytokine signaling and
were differentially expressed in cGVHDþ versus cGVHD 
donors. Analyzing several genes involved in a common
signaling cascade has special interest because it provides a
unique opportunity to validate the biological coherence of
differentially expressed genes. Preliminary analysis of Table
S1 and Table S2 showed that at least ﬁve cGVHD-predictive
genes were components of the transforming growth factor-b
(TGF-b) signaling pathway. These ﬁve genes were selected for
quantitative PCR studies. To further evaluate the possible
role of the TGF-b pathway, we also tested TGIF and TGF-b-
induced (TGFBI) (which were not present on the microarrays),
which are transcriptional targets of TGF-b. Performance of
individual genes was evaluated using univariate Student’s t-
test and LDA. The statistical signiﬁcance corresponds to t-test
p-value, whereas classiﬁcation performance (sensitivity, spe-
ciﬁcity, and overall accuracy) was derived from LDA.
qRT-PCR did not conﬁrm the predictive value of nine
genes (Table 2). This result can be explained by the limited
sample size and the idiosyncrasies of the two mRNA-
measurement procedures (e.g., cross-hybridization and splic-
ing variants) [34]. Out of the 26 genes tested, 17 were
differentially expressed in GVHDþ and GVHD  donors
(Table 2): 15 genes selected from Table S1 and Table S2
(they showed consistent change directionality in microarrays
Figure 1. Study Design
Donor and recipient T cells were obtained on days 0 and 365,
respectively. Total RNA from purified CD4
þ and CD8
þ T cells was
reversed transcribed and hybridized on the human H19K array (donor
and recipient T cells) and the ImmunArray (donor T cells) from The
Microarray Centre of The Toronto University Health Network.
doi:10.1371/journal.pmed.0040023.g001
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genes. The statistical signiﬁcance (t-test p- value) of individual
cGVHD-predictive genes ranged from 0.046 to 0.0005, and
their GVHD-predictive accuracy (LDA) from 63% to 80%. Of
note, there was a weak negative correlation (r ¼  0.53, p ¼
0.03) between the speciﬁcity and sensitivity of the 17 genes.
Thus, some genes were better in predicting the occurrence of
GVHD than its absence, and vice versa for other genes. PRF1
showed the best speciﬁcity (Figure 3; Table 2). PRF1 codes for
perforin, whose high expression in CD8
þ Tc e l l sw a s
associated with occurrence of GVHD. SMAD3, a transcription
factor that is activated following TGF-b binding, showed the
highest sensitivity (Figure 3; Table 2). High levels of SMAD3
transcripts in CD4
þ T cells correlated with absence of GVHD.
Based on the LDA-generated class separatrix, the speciﬁcity
and sensitivity for SMAD3 were 53% and 89% with an overall
accuracy of 73%. We repositioned post-hoc the separatrix in
order to have all cGVHDþ donors on one side of the
separatrix (hereafter referred to as the 100% cGVHDþ
separatrix). This new separatrix, which by deﬁnition in-
creased the sensitivity to 100%, also increased the overall
accuracy to 79% without changing the speciﬁcity (Figure 3).
Thus, low levels of SMAD3 were found in all GVHDþ and
some GVHD  donors, while all donors expressing high levels
of SMAD3 were GVHD  (Figure 3). Mechanistically, this
suggests that high levels of SMAD3 are sufﬁcient (but not
necessary) to prevent GVHD, while low levels are necessary
(but not sufﬁcient) for the occurrence of GVHD.
One major point highlighted by gene-expression proﬁling
studies is the primacy of pathways over the effects of
individual genes (pathways ultimately deﬁne the proﬁles)
[36,40]. With this in mind, a most salient ﬁnding was that all
components and targets of the TGF-b pathway tested by qRT-
PCR were differentially expressed in GVHDþ versus GVHD 
donors (Table 2). Compared with GVHDþ donors, GVHD 
donors showed up-regulation of EP300, FURIN, FNBP3,
SMAD3, TGFBI, and TGIF, and repression of PRF1. From a
pathway perspective, that expression proﬁle is entirely
consistent and points to increased TGF-b signaling in T cells
from GVHD  relative to GVHDþ donors [41–47]. The ten
other cGVHD-predictive genes whose differential expression
was conﬁrmed by qRT-PCR are involved in regulation of cell
growth and proliferation (AKT2, ATBF1, CD24, CD151,
MYCL1, NFAT5, NMI, SIL, SH3KBP1, and TCIRG1) [48–57].
PIAs using a pairwise interaction model. A global approach
is required to properly understand cellular responses,
because interpathway cross-talk and other properties of
networks reﬂect underlying complexities that cannot be
explained by the consideration of individual pathways in
isolation [58,59]. In their simplest form, gene–gene inter-
actions may be phenomenologically competitive or syner-
gistic. We posited that such interactions might be reﬂected in
particular gene-pair expression patterns. For example, if
gene X and gene Y represent a competitive interaction, the
ratio of gene Y/X expression should determine GVHD
outcome (e.g., presence and absence of GVHD will correlate
with high and low Y/X ratios, respectively). Alternatively, for
synergistic interactions, the occurrence of GVHD should be
regulated by the product of genes’ X 3 Y activities. We
therefore examined gene-pair expression ratios and products
within the context of competitive and synergistic models. To
this end, we evaluated the gene pairs formed by the 15
GVHD-predictive genes validated in both microarray and
qRT-PCR experiments (Table 2). The total number of gene
pairs analyzed corresponds to n(n   1)/2 (i.e., 105). We asked
whether CPIA and SPIA would highlight gene pairs whose p-
value for cGVHD versus no GVHD was at least 10-fold lower
than that of constituent genes. A total of four gene pairs
satisﬁed this stringent criterion (Figure 4A). PIAs suggest that
NFAT5, a transcription factor that regulates gene expression
induced by osmotic stress [53], has competitive interactions
with SH3KBP1 (alias CIN85), which interacts with CBL (a
negative regulator of immune signaling) [56], and with PRF1,
a quintessential component of CD8
þT cell granule exocytosis
cytotoxicity pathway [60]. Likewise, PIAs suggest that PRF1
has competitive interactions with TCIRG1 (alias TIRC7), a
negative regulator of T cell activation and cytokine response
[57]; and that CD151, a negative regulator of Ag-induced T
cell proliferation [51], collaborates synergistically with SIL, a
gene whose expression is associated with cell proliferation
[61]. From a mechanistic perspective, these data suggest that
interactions between the four pairs’ constituent genes are
biologically relevant and should be investigated.
Gene pairs discovered by PIA can provide better perform-
ance than constituent single genes in terms of prediction
accuracy. Performance gain is illustrated by further analyses
of the SH3KBP1/NFAT5 gene pair using LDA and two class-
separatrices: the LDA-generated separatrix and the 100%
Figure 2. GVHD Predictive Genes Identified by One-Dimensional
Analyses
Searches were performed using two methods: a linear discriminant-
analysis–based approach and statistical t-test.
(A) Number of genes showing a GVHD-predictive accuracy   65% and p
  0.05.
(B and C) Data from the H19K and ImmuArray were pooled. Among
GVHD-predictive genes, Venn diagrams represent counts relationships
between CD4
þ versus CD8
þ T-cell gene profiles (B) and aGVHD versus
cGVHD predictive-genes (C).
doi:10.1371/journal.pmed.0040023.g002
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Prediction of Graft-Versus-Host DiseasecGVHDþseparatrix (designed to maximize sensitivity) (Figure
4). Compared to the LDA-generated separatrix, the 100%
cGVHDþ separatrix increased the sensitivity by 22%–39%
without compromising overall accuracy (Figure 4). Using the
LDA-generated separatrix, the SH3KBP1/NFAT5 gene pair
provided a 6% gain in both sensitivity and overall accuracy
compared with single genes. With the 100% cGVHDþ
separatrix (which by deﬁnition gives a 100% sensitivity), the
overall accuracy gain was 8%. From a clinical standpoint,
these data suggest that PIAs can identify gene pairs with
greatly enhanced predictive accuracies and stronger p-values
compared to their constituent genes. Furthermore, they
imply that in further studies with a larger number of
participants, higher-order combinatorial searches could
signiﬁcantly improve the prediction performance of gene-
expression proﬁling [30].
Multiple training-test dataset split cross-validation. We can
be conﬁdent that genes with good cGVHDþ- and cGVHD -
differentiating t-test p-values over the complete set of
samples have a statistically signiﬁcant ability to distinguish
between these classes (in terms of rejecting the equal means
null hypothesis). However, the assessment of LDA classiﬁca-
tion accuracy on a single set of samples may not be robust,
since accuracy could be highly sensitive to chance ﬂuctua-
tions of measurement points in the vicinity of the separatrix.
Such situations might not have a large impact on p-value, but
can disproportionately affect accuracy assessments. To
establish whether cGVHDþ/  discrimination accuracy may
be generalizable and robust, we need to determine the
accuracy of the model prediction on test datasets that are
independent (with regard to sampling) of the training
datasets from which the predictive LDA models are derived.
However, a single instance of training-test dataset compar-
ison can be considered neither representative nor robust,
since it is potentially sensitive to idiosyncratic ﬂuctuations of
datapoints around the separatrix. We therefore determined
the robust average accuracy over many independently
generated test datasets for each gene, on the basis of different
selections of training-set data for each gene [30], using
conventional cross-validation procedures [29]. These analyses
were performed on the 17 single genes (Table 2) and the PIA
variables representative of the four gene pairs (Figure 4A)
that were predictive of cGVHD occurrence. Speciﬁcally, for
each gene, we carried out 500 different 60% training samples
and 40% test-samples dataset splits by randomly assigning
(for each data split) 60% of the respective cGVHDþ and
cGVHD  samples to a training dataset, and the remaining
40% of the samples to the respective test datasets. For CD4
þ
cells, 11 cGVHDþ and nine cGVHD  samples were selected
randomly for training datasets, while the seven cGVHDþand
six cGVHD  remaining samples were used in test datasets.
For CD8
þ cells, 11 cGVHDþ and ten cGVHD  samples were
selected randomly for training datasets, while the remaining
seven cGVHDþand seven cGVHD samples were used in test
datasets. The test dataset accuracy was determined separately
for each of the 500 training/test random-sampling splits by
using the LDA-predictive model separatrix from the corre-
sponding training dataset. We emphasize that each test
Table 2. qRT-PCR Analyses of GVHD-Predictive Genes
Gene Cell Type qRT-PCR:
cGVHDþ Versus
cGVHD  p-Values
Specificity Sensitivity Accuracy
SMAD3
a,c CD4
þ 0.0005 53% 89% 73%
TCIRG1
a CD4
þ 0.0005 73% 78% 76%
ATBF1
a CD4
þ 0.0013 67% 83% 76%
SIL
a CD4
þ 0.0017 60% 83% 73%
TGIF
a,c,d CD4
þ 0.0018 60% 83% 73%
AKT2
a CD4
þ 0.0020 67% 72% 70%
CD151
a CD4
þ 0.0020 73% 78% 76%
FNBP3
a,c CD4
þ 0.0021 60% 83% 73%
CD24
a CD8
þ 0.0026 65% 72% 69%
PRF1
b,c CD8
þ 0.0037 88% 72% 80%
EP300
a,c CD4
þ 0.0040 47% 78% 64%
TGFBI
a,c,d CD4
þ 0.0043 67% 61% 64%
SH3KBP1
b CD8
þ 0.0059 65% 61% 63%
FURIN
a,c CD4
þ 0.0095 73% 56% 64%
NMI
a CD4
þ 0.0099 60% 67% 64%
NFAT5
a CD8
þ 0.0193 71% 72% 71%
TCIRG1
a CD8
þ 0.0464 76% 56% 66%
STK38
a, IL1R1
b CD4
þ NS — — —
PDCD8
b, FAF1
b CD4
þ NS — — —
IL6R
a, MYCL1
b CD4
þ NS — — —
SH3KBP1
b, RAN
a CD4
þ NS — — —
RAN
b CD8
þ NS — — —
‘‘Specificity’’: true negatives/(true negatives þ false positives); ‘‘Sensitivity’’: true positives/(true positives þ false negatives).
aGenes repressed in cGVHDþ relative to cGVHD  donors.
bGenes overexpressed in cGVHDþ relative to cGVHD  donors.
cComponents and targets of the TGF-b signaling pathway.
dTGF-b target genes that were not represented on the microarrays.
NS, not significant by qRT-PCR.
doi:10.1371/journal.pmed.0040023.t002
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Prediction of Graft-Versus-Host Diseasedataset-accuracy determination for each gene was carried out
500 separate times on randomly chosen dataset splits, each
time using a predictive model that has never been exposed to
the test data.
We report for each gene the robust cross-validation
ensemble average test-set accuracy and its standard deviation,
as well as bar graphs depicting occurrences of speciﬁc
accuracies in 10% accuracy increments (Figure 5). We found
that the average test-set cross-validation accuracy was 71% 6
10%, and that genes such as CD151 for CD4
þcells achieved an
accuracy of 77% 6 9%, and PRF1 for CD8
þ cells achieved
76% 6 10%. Notably, the test-set cross-validation accuracy of
gene pairs identiﬁed by PIA often outperforms that of single
genes. For example, the CD151–SIL gene pair achieved 80%
6 9%, while its constituent genes CD151 and SIL provided
accuracies of 77% 6 9% and 69% 6 10%, respectively. In
addition, in Figure 5 we see a conspicuous shift of
occurrences of accuracies from the 70% and 80% histogram
bins for the constituent genes to the 90% and 100% bins for
the gene pairs. These data provide strong evidence that the 17
genes and four gene pairs reported herein not only show
statistically signiﬁcant differences between cGVHDþ and
cGVHD  donors, but also that these differences are sub-
stantial in magnitude and robustly provide higher than 70%
accuracies overall. We therefore infer that the robust
discrimination performance of these genes and gene pairs
could be of clinical value for cGVHD prediction.
The Microarray-Based Donor Gene Profile Persists Long-
Term in the Recipient
To determine whether differences in donor gene-expres-
sion proﬁles were transferable, we evaluated whether they
persisted in the recipient. All our recipients were adults that
were given a myeloablative-conditioning regimen and re-
ceived a non-T cell–depleted AHCT. In these conditions,
essentially all T cells on day 365 are donor-derived [62–65].
We therefore studied the relationship between the donor
gene proﬁles on day 0 (t0) and the recipient proﬁles on day
365 (t3). In other words, we compared the transcriptome of T
cells derived from a single zygote (the donor) but residing in
two types of environments (the donor and the recipient). To
get a manageable yet broad basis for analyses, we included
two gene sets tested on the H19K chip: the top 400 genes
showing differential expression in GVHDþ versus GVHD 
donors on day 0, combined with the top 400 genes showing
differential expression in GVHDþ versus GVHD  recipients
on day 365 (Table S3). Because of overlap between the two
gene sets, a total of 711 genes was analyzed. Genes that
exhibited little variation across arrays were excluded because
they do not contribute useful information for distinguishing
Figure 3. LDA-Based Scatterplot of qRT-PCR Data for SMAD3 and PRF1
Levels of (A) SMAD3 and (B) PRF1 transcripts were assessed in CD4
þ and CD8
þ T cells, respectively. Data for all donors tested by qRT-PCR were ranked
according to relative gene expression levels. Thick horizontal black line corresponds to the LDA separatrix. For SMAD3, a computationally repositioned
separatrix for 100% GVHDþ discrimination is shown (red line).
doi:10.1371/journal.pmed.0040023.g003
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Prediction of Graft-Versus-Host DiseaseFigure 4. Competitive and Synergistic Interactions between GVHD-Predictive Genes
(A) PIA identified four gene pairs whose p-value for cGVHD prediction was at least 10-fold lower than that of constituent genes. LDA-based scatterplots
of qRT-PCR data for (B) NFAT5, (C) SH3KBP1, and (D) the NFAT5/SH3KBP1 gene pair. Dotted lines represent LDA-generated separatrices. Red lines
correspond to 100% cGVHDþ separatrices (designed to maximize sensitivity).
doi:10.1371/journal.pmed.0040023.g004
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Prediction of Graft-Versus-Host Diseaseamong specimens [36]. The basic postulate underlying our
analyses was that if the donor proﬁle is largely transferred to
the recipient, correlation between a donor on day 0 and its
recipient on day 365 (t0i   t3i) would be stronger than (i)
correlation of that donor with other donors on day 0 (t0i t0)
and (ii) correlation of that recipient with other recipients on
day 365 (t3i   t3). The reverse would be true, and the donor-
speciﬁc characteristics should be ‘‘washed out,’’ if the gene-
expression proﬁles were either unstable or regulated primar-
ily by adaptive (environmental) effects.
Figure 5. Multiple Training-Test Dataset Split Cross-Validation
For each single gene (n¼17, blue) and gene pairs (n¼4, red), we carried out 500 different 60% training samples and 40% test samples dataset splits by
randomly assigning 60% of the respective cGVHDþand cGVHD samples to a training dataset and the remaining 40% of the samples to the respective
test datasets. The test dataset accuracy was determined separately for each of the 500 training/test random sampling splits by using the LDA predictive
model separatrix from the corresponding training dataset. Bar graphs show the occurrence of specific accuracies in 10% accuracy increments. Numbers
in each panel represent the mean test-set accuracy (%) 6 standard deviation.
doi:10.1371/journal.pmed.0040023.g005
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Prediction of Graft-Versus-Host DiseaseWe found that the average gene-expression proﬁle corre-
lation among corresponding donor–recipient pairs (t0i   t3i)
was consistently higher than the average correlation among
donors (t0i t0) and among recipients (t3i t3) (Figure 6). This
was true for CD4
þ and CD8
þ T cells, in recipients that were
cGVHDþ and those that were cGVHD  (Figure 6). Thus,
interindividual differences in expression of GVHD-associated
transcripts are remarkably stable over time (365 days).
Stability over time increases their potential value as predictive
markers. The donor gene-expression proﬁles are also very
robust since they persist following transfer in a different host
(the recipient) even in the presence of confounding disease-
related factors (cGVHD and its treatment). The stability and
‘‘transferability’’ of the GVHD-linked gene-expression pro-
ﬁles point to a major genetic (as opposed to environmental)
inﬂuence. Since donors and recipients were siblings it is
formally possible that the similar environments (nonhemato-
lymphoid cells) in which T cells resided may have contributed
to the transferability of the T cell-expression proﬁles.
Discussion
Several conclusions can be drawn from our work. First, the
donor gene-expression proﬁle has a dominant inﬂuence on
the occurrence of aGVHD and cGVHD in the recipient.
Second, extensive studies on cGVHD prediction revealed that
the ‘‘dangerous donor’’ trait (occurrence of GVHD in the
recipient) is under polygenic control and is determined by
competitive and synergistic gene interactions. Third, the risk
of cGVHD is shaped by the activity of genes that regulate
diverse cell functions in donor T cells, including TGF-b
signaling and cell proliferation. Finally, the donor gene
proﬁle persists long-term in the recipient. We wish to
emphasize that several convergent pieces of evidence under-
pin the robustness of conclusions presented herein: (i) in
microarray experiments, the donor gene proﬁle deﬁned on
day 0 showed exceedingly strong correlation with that of
recipient CD4
þand CD8
þT cells harvested on day 365; (ii) for
most genes tested by qRT-PCR, differential gene expression
between cGVHDþ and cGVHD  donors was conﬁrmed to be
robust, on the basis of statistical tests and computational
analysis of independent training-test datasets; (iii) from a
pathway perspective, differential expression of TGF-b-related
transcripts was entirely consistent with increased TGF-b
signaling in T cells from cGVHD  relative to cGVHDþ
donors. Compared with cGVHDþ donors, cGVHD  donors
showed higher levels of activating components of the TGF-b
signaling pathway (EP300, FNBP3, FURIN, SMAD3) and of
genes induced by TGF-b (TGFBI, TGIF) but lower expression
of PRF1, which is repressed by TGF-b (Table 2). Notably,
transcripts for TGF-b (TGFB1) and its receptors (TGFBR2 and
TGFBR3) were represented on the microarrays and were not
differentially expressed in T cells from cGVHDþ relative to
cGVHD  donors (unpublished data). Collectively, these data
suggest that under basal conditions interindividual variations
exist in TGF-b signaling activity. Moreover, they imply that
these interindividual variations are stable over time (Figure 6)
and are due, at least in part, to differential expression of
intracellular TGF-b pathway components rather than mem-
brane-associated factors. The latter idea is consistent with
recent data on Wnt and TGF-b signaling. Among thymocyte
subsets, differential responsiveness to Wnt signals is not
Figure 6. The Pre-AHCT Donor Gene Expression Profile Correlates with
the Recipient Expression Profile Examined One Year Post-AHCT
The Pearson correlation coefficient (rho) over the expression vectors of
711 informative genes (listed in Table S3) was calculated between
members of all matching donor–recipient pairs, and all donor–donor and
recipient–recipient pairs, and then averaged for each group. Bar graphs
show the mean Pearson correlation coefficient between individual
donors on day 0 with their recipient on day 365 (t0i   t3i) (red bar),
between individual donors and all other donors on day 0 (t0i   t0)
(yellow bar), and between individual recipients and all other recipients
on day 365 (t3i   t3) (blue bar). Data are from all (40) donor–recipient
pairs (A), or from pairs in which the recipient presented cGVHD (B), or not
(C). Error bars represent the standard error of the mean. The vector of (t0i
 t3i) correlations was compared to the vectors of (t0i t0) and (t3i t3)
correlations using Student’s t-test, to determine whether the differences
between these observed sample pair correlation groups are statistically
significant. t-Test p-values relative to (t0i   t3i) are labeled as follows: *,
0.01 , p , 0.05; **, 0.001 , p , 0.01; ***, p , 10
 6.
doi:10.1371/journal.pmed.0040023.g006
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but rather by the balance between activating and inhibiting
intracellular components of the Wnt pathway (e.g., b-catenin,
c-catenin, and TCF-1) [66]. In addition, two recent studies
demonstrated that modulation of SMAD proteins such as
SMAD3 was sufﬁcient to regulate the strength of TGF-b
signaling [67,68].
To the best of our knowledge, our study is the ﬁrst to
present evidence that differential gene expression in donor
CD4
þ and CD8
þ T cells is predictive of the risk of GVHD in
the recipient. As mentioned in the Introduction, histoincom-
patibility is necessary but not sufﬁcient to elicit GVHD. On
the basis of our data, we propose that the occurrence of
GVHD is determined by another key factor: a dangerous
donor (strong alloresponder). Further studies are required to
decipher how this complex polygenic trait is regulated.
Nevertheless, the concept that TGF-b signaling in donor cells
has a protective role against GVHD is consistent with the
well-known pivotal function of TGF-b in maintaining
tolerance and preventing the development of immunopa-
thology [42]. TGF-b is the cytokine expressed constitutively at
highest levels in lymphoid and nonlymphoid organs [69], and
its pervasive inﬂuence on immune responses results from
pleiotropic effects. TGF-b blocks T cell proliferation, inhibits
differentiation of Th1 (T helper class 1) cells and CTLs
(cytotoxic T lymphocytes), and promotes expansion as well as
maintenance of CD4
þCD25
þ regulatory T cells that can
inhibit GVHD [42,70–77]. Moreover, recent studies in mice
have shown that production of TGF-b by donor T cells early
after AHCT attenuates GVHD, and that neutralization of
TGF-b signiﬁcantly increases the severity of GVHD [78]. Since
AHCT is generally used to treat hematologic malignancies,
t h ef a c tt h a tT G F - b has a tumor suppressor role in
hematologic malignancies [79] might constitute an additional
beneﬁt associated with induction of the TGF-b pathway.
Among cGVHD-predictive genes that are not related to the
TGF-b pathway, TCIRG1 (alias TIRC7) is of particular interest,
since it ranked ﬁrst in terms of statistical signiﬁcance for
prediction of cGVHD (Table 2). GVHD  donors expressed
higher levels of TCIRG1 transcripts than GVHDþ donors.
This is consistent with the function of TCIRG1, which
colocalizes with the T cell receptor and mediates inhibitory
signals that lead to up-regulation of CTLA4 and repression of
interleukin-2 and interferon-c [57,80]. Remarkably, TCIRG1-
speciﬁc stimulatory antibodies signiﬁcantly prolonged heart
and kidney graft survival [81,82].
During the early months post-AHCT, recipient T cells derive
to a large extent from proliferation of mature donor T cells
present in the graft. However, by one year post-AHCT,
recipient T cells derive mainly, if not exclusively, from
development of donor-derived hematolymphoid progenitors
in the recipient’s thymus [83–85]. Thus, on day 365, recipient T
cells originate essentially from donor hematopoietic stem cells
as opposed to donor post-thymic T cells. The fact that the pre-
AHCT donor gene proﬁle correlates with the recipient proﬁle
one year post-AHCT (Figure 6) is therefore quite remarkable.
These data provide compelling, albeit indirect, evidence that a
signiﬁcant portion of the differential gene proﬁles between
GVHDþand GVHD donors is imprinted at the hematopoietic
stem cell level. Moreover, stability of the gene-expression
proﬁles in the donor and recipient over a one-year period
suggests that the proﬁles result from inherited genetic traits as
opposed to environmentalfactors. Geneticlinkage analyseswill
be needed to test directly this inference.
Can identiﬁcation of strong versus weak alloresponders be
used to select AHCT donors? The predictive value of our best
genes was about 80% based on the LDA model separatrix
(Table 2). However, predictive models and separatrices can be
ﬁne tuned for clinical decision-making to either optimize
sensitivity or speciﬁcity. An increase in sensitivity usually
comes at the expense of a decrease in speciﬁcity, and vice
versa. Given that the avoidance of GVHD is usually para-
mount, one would expect that a bias toward the best
achievable sensitivity, allowing for the most reliable (or total)
elimination of GVHDþ donors (while not eliminating too
many donor candidates), would be clinically desirable (Figure
3 and Figure 4). Interestingly, PIA based on a pairwise gene-
interaction model suggested that some genes have synergistic
or competitive interactions that lead to increased predictive-
model performance (Figure 4). This result also suggests that
higher-order combinatorial searches beyond two genes could
improve signiﬁcantly the predictive performance of gene-
expression proﬁling [30]. Thus, predictive models limited to a
set of ten to 20 genes may achieve even greater than 80%
accuracy and the robustness required for dependable AHCT
donor selection. However, higher-order predictive variable
combinations do require the support of many more samples
to prevent overﬁtting of the model. Cogent assessment of this
question will therefore necessitate expression proﬁling of
genes identiﬁed herein in larger cohorts of participants.
Thus, before gene-expression proﬁling can be widely used to
guide clinical decision-making, it must be validated at other
centers, in a wider range of patients. Similar to a recently
reported index for post-AHCT assessment of GVHD severity
[86], we envision predictive models based on pre-AHCT
donor-expression proﬁling as an ‘‘evolving’’ evidence-based
process for determining the risk of GVHD, to be recalibrated
over time to account for changes in practice. As a corollary, a
gene set that can identify strong alloresponders should also
have predictive value for rejection of solid organ grafts. In
summary, the results presented here could represent the basis
of a breakthrough in transplantation medicine by helping
selection of low-risk donors for AHCT, and tailoring the
immunosuppressive regimens given to the recipient accord-
ing to the risk of GVHD (AHCT) or rejection (solid organ).
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Prediction of Graft-Versus-Host DiseaseEditors’ Summary
Background. Human blood contains red blood cells, white blood cells,
and platelets, which carry oxygen throughout the body, fight infections,
and help blood clot, respectively. Normally, blood-forming (hemato-
poietic) stem cells in the bone marrow (and their offspring, peripheral
blood stem cells) continually provide new blood cells. Tumors that arise
from the bone marrow (such as leukemia and lymphoma, two types of
hematopoietic tumor) are often treated by a bone marrow or peripheral
blood stem cell transplant from a healthy donor to provide new blood-
forming stem cells, as a follow-up to chemotherapy or radiotherapy
designed to eradicate as much of the tumor as possible. This procedure
is called allogeneic hematopoietic cell transplantation (AHCT)—the word
allogeneic indicates that the donor and recipient are not genetically
identical. When solid organs (for example, kidneys) are transplanted, the
recipient’s immune system can recognize alloantigens (proteins that vary
between individuals) on the donor organ as foreign and reject it. To
reduce the risk of rejection, the donor and recipient must have identical
major histocompatibility complex (MHC) proteins. MHC matching is also
important in AHCT but for further reasons. Here, donor T lymphocytes (a
type of white blood cell) can attack the skin and other tissues of the host.
This graft versus host disease (GVHD) affects many people undergoing
AHCT despite MHC matching either soon after transplantation (acute
GVHD) or months later (chronic GVHD). As an aside, the transplant may
also act against the tumor itself—this is known as a graft versus leukemia
effect.
Why Was This Study Done? GVHD can usually be treated with drugs
that damp down the immune system (immunosuppressive drugs), but it
would be preferable to avoid GVHD altogether. Indeed, GVHD continues
to be the leading cause of nonrelapse mortality following AHCT.
Unfortunately, what determines who will develop GVHD after MHC-
matched AHCT is unclear. Although GVHD only develops if there are
some mismatches in histocompatibility antigens between the donor and
host, it does not inevitably develop. Until now, scientists have mainly
investigated whether differences between ACHT recipients might explain
this observation. But, in this study, the researchers have examined the
donors instead to see whether differences in their immune responses
might make some donors stronger ‘‘alloresponders’’ than others and
consequently more likely to cause GVHD.
What Did the Researchers Do and Find? The researchers used a
molecular biology technique called microarray expression profiling to
examine gene expression patterns in the T lymphocytes of peripheral
blood stem cell donors. From these patterns, they identified numerous
genes whose expression levels discriminated between donors whose
MHC-identical transplant recipient developed GVHD after AHCT (GVHD
þ
donors) and those whose recipient did not develop GVHD (GVHD
 
donors). The researchers confirmed that the expression levels of 17 of
these genes discriminated between GVHD
þ and GVHD
  donors using a
second technique called quantitative reverse transcriptase polymerase
chain reaction. Many of these genes are involved in TGF-b signaling (TGF-
b is a protein that helps to control the immune system), cell growth, or
proliferation. The researchers also identified four gene pairs that
interacted with each other to determine the likelihood that a given
donor would induce GVHD. Finally, the researchers computationally
retested their data and showed that the measurement of expression
levels of each of these genes and of the four interacting gene pairs could
correctly identify a donor sample likely to cause GVHD in up to 80% of
samples.
What Do These Findings Mean? These findings provide the first
evidence that the donor’s gene expression profile influences the
development of GVHD in the recipient after AHCT. The researchers
suggest that a ‘‘dangerous donor’’ (strong alloresponder) is a key factor
in determining whether GVHD occurs after AHCT and propose that gene
expression profiling of donor T lymphocytes might identify those donors
likely to cause GVHD. Before this approach can be used to reduce the
incidence of GVHD after AHCT, these findings need to be confirmed in
many more donors. Also, the development of a test that is accurate
enough for clinical use—one that does not miss dangerous donors but
does not discard too many safe donors—may require the identification
of larger groups of interacting genes. But, if it survives further
investigation, the concept of a dangerous donor could represent an
important advance in transplantation medicine, one that could help
clinicians select low-risk donors for AHCT and tailor patients’ immuno-
suppressive drug regimens according to their donor-determined risk of
GVHD.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/doi:10.1371/journal.pmed.
0040023.
  The National Marrow Donor Program provides information for patients
and physicians on all aspects of hematopoietic stem cell transplanta-
tion, including GVHD
  The MedlinePlus encyclopedia has pages on bone marrow transplants,
GVHD and transplant rejection
  The US National Cancer Institute has a factsheet on bone marrow and
peripheral blood stem cell transplantation
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